- BioCina and NovaCina merge to form a fully integrated CDMO offering end-to-end biopharmaceutical and small molecule services.
- The new BioCina will feature expanded capabilities, including cell line development, drug substance production, and sterile fill-finish.

BioCina, a global contract development and manufacturing organisation (CDMO), has announced a strategic merger with NovaCina. The merger integrates both companies’ expertise to deliver a seamless suite of end-to-end manufacturing solutions for the biopharmaceutical and small molecule industries.
The new entity, retaining the BioCina name, combines the process development and microbial, plasmid DNA, and mRNA manufacturing capabilities of BioCina’s Adelaide, South Australia facility with NovaCina’s state-of-the-art sterile fill-finish plant in Perth, Western Australia. The merger positions BioCina to meet rising demand for comprehensive CDMO services in markets across the US, Europe, Asia, and Australia.
Mark W. Womack, CEO of BioCina, who has been instrumental in driving the company’s growth, will continue in his role. Highlighting the benefits of the merger, he stated: “This merger solidifies our position in the industry as the most reliable and client-centric end-to-end CDMO for the global biopharmaceutical and small molecule industry.”
The partnership emphasises agility and reliability, with BioCina’s regulatory approvals from the FDA, EMA, TGA, and Health Canada reinforcing its ability to serve global markets. Clients will also benefit from Australia’s 48.5% tax incentive for CDMO programmes, offering a cost-efficient solution for drug developers.
Masood Tayebi, Co-Founder and CEO of Bridgewest Group, the parent company of both firms, expressed confidence in the merger: “The cohesion of these two companies is quite ideal. Together, they will boost the industry’s capabilities and standards, providing an unparalleled offering.”
The new BioCina aims to cater to a growing demand for streamlined, high-quality manufacturing solutions, delivering phase-appropriate services with exceptional reliability and a client-centric approach.